Neuphoria Therapeutics Inc.
NEUP · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Valuation | ||||
| PEG Ratio | 0.01 | 0.00 | -0.00 | -0.44 |
| FCF Yield | -14.33% | 638.45% | 0.85% | -0.42% |
| EV / EBITDA | -0.87 | 16.63 | 73.70 | -255.89 |
| Quality | ||||
| ROIC | -38.21% | -2.07% | 65.03% | -36.96% |
| Gross Margin | 0.00% | 97.89% | 98.90% | 0.00% |
| Cash Conversion Ratio | 0.38 | -0.19 | 1.02 | 1.73 |
| Growth | ||||
| Revenue 3-Year CAGR | 2,101,495.76% | 2,101,495.76% | 2,921,765.75% | 1,022,882.11% |
| Free Cash Flow Growth | -105.16% | 542.31% | 441.08% | 24.25% |
| Safety | ||||
| Net Debt / EBITDA | 0.92 | 16.64 | -0.93 | 1.33 |
| Interest Coverage | 0.00 | 0.00 | 0.00 | 0.00 |
| Efficiency | ||||
| Inventory Turnover | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -491.84 | -313,808.93 | -254.67 | 2.99 |